CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Viking Therapeutics, Inc. - VKTX CFD

85.04
10.67%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.31
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Viking Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 76.84
Open* 82.41
1-Year Change* 650.55%
Day's Range* 82.38 - 86.52
52 wk Range 8.25-25.72
Average Volume (10 days) 2.67M
Average Volume (3 months) 51.59M
Market Cap 2.09B
P/E Ratio -100.00K
Shares Outstanding 100.03M
Revenue N/A
EPS -0.92
Dividend (Yield %) N/A
Beta 0.52
Next Earnings Date Feb 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 85.04 4.33 5.36% 80.71 87.65 80.32
Feb 29, 2024 76.84 -13.33 -14.78% 90.17 92.95 74.95
Feb 28, 2024 94.01 3.31 3.65% 90.70 99.09 86.59
Feb 27, 2024 84.91 17.41 25.79% 67.50 89.83 57.41
Feb 26, 2024 38.38 2.35 6.52% 36.03 38.41 35.70
Feb 23, 2024 37.35 1.71 4.80% 35.64 38.59 35.53
Feb 22, 2024 35.55 0.57 1.63% 34.98 37.93 34.94
Feb 21, 2024 35.12 -0.20 -0.57% 35.32 36.71 33.95
Feb 20, 2024 35.67 -0.47 -1.30% 36.14 37.24 34.18
Feb 16, 2024 36.10 4.56 14.46% 31.54 37.12 31.52
Feb 15, 2024 31.76 -0.33 -1.03% 32.09 32.34 30.89
Feb 14, 2024 32.17 0.83 2.65% 31.34 33.86 30.95
Feb 13, 2024 30.54 0.51 1.70% 30.03 31.20 29.75
Feb 12, 2024 31.65 0.61 1.97% 31.04 31.68 29.83
Feb 9, 2024 30.48 1.28 4.38% 29.20 31.92 29.00
Feb 8, 2024 28.84 3.09 12.00% 25.75 29.29 25.29
Feb 7, 2024 24.41 -0.29 -1.17% 24.70 24.85 23.75
Feb 6, 2024 24.56 1.32 5.68% 23.24 24.58 23.02
Feb 5, 2024 24.59 1.18 5.04% 23.41 24.97 22.54
Feb 2, 2024 23.39 -0.37 -1.56% 23.76 23.81 22.46

Viking Therapeutics, Inc. Events

Time (UTC) Country Event
Wednesday, April 24, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Viking Therapeutics Inc Earnings Release
Q1 2024 Viking Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, June 12, 2024

Time (UTC)

15:00

Country

US

Event

Viking Therapeutics Inc Annual Shareholders Meeting
Viking Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 70.355 55.682 42.662 32.687 26.161
Selling/General/Admin. Expenses, Total 16.121 10.701 10.731 9.128 7.121
Research & Development 54.234 44.981 31.931 23.559 19.04
Operating Income -70.355 -55.682 -42.662 -32.687 -26.161
Interest Income (Expense), Net Non-Operating 1.488 0.692 3.167 6.908 2.7
Other, Net 0 1.398
Net Income Before Taxes -68.867 -54.99 -39.495 -25.779 -22.063
Net Income After Taxes -68.867 -54.99 -39.495 -25.779 -22.063
Net Income Before Extra. Items -68.867 -54.99 -39.495 -25.779 -22.063
Net Income -68.867 -54.99 -39.495 -25.779 -22.063
Income Available to Common Excl. Extra. Items -68.867 -54.99 -39.495 -25.779 -22.063
Income Available to Common Incl. Extra. Items -68.867 -54.99 -39.495 -25.779 -22.063
Diluted Net Income -68.867 -54.99 -39.495 -25.779 -22.063
Diluted Weighted Average Shares 76.8336 77.198 72.597 71.9591 57.58
Diluted EPS Excluding Extraordinary Items -0.89631 -0.71232 -0.54403 -0.35825 -0.38317
Diluted Normalized EPS -0.89631 -0.71232 -0.54403 -0.35825 -0.38317
Total Extraordinary Items
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 27.265 23.74 20.537 20.283 16.196
Selling/General/Admin. Expenses, Total 8.886 9.823 9.529 4.105 4.237
Research & Development 18.379 13.917 11.008 16.178 11.959
Operating Income -27.265 -23.74 -20.537 -20.283 -16.196
Interest Income (Expense), Net Non-Operating 4.731 4.515 1.006 0.724 0.423
Net Income Before Taxes -22.534 -19.225 -19.531 -19.559 -15.773
Net Income After Taxes -22.534 -19.225 -19.531 -19.559 -15.773
Net Income Before Extra. Items -22.534 -19.225 -19.531 -19.559 -15.773
Net Income -22.534 -19.225 -19.531 -19.559 -15.773
Income Available to Common Excl. Extra. Items -22.534 -19.225 -19.531 -19.559 -15.773
Income Available to Common Incl. Extra. Items -22.534 -19.225 -19.531 -19.559 -15.773
Diluted Net Income -22.534 -19.225 -19.531 -19.559 -15.773
Diluted Weighted Average Shares 99.846 99.01 78.352 76.584 76.5054
Diluted EPS Excluding Extraordinary Items -0.22569 -0.19417 -0.24927 -0.25539 -0.20617
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.22569 -0.19417 -0.24927 -0.25539 -0.20617
Other, Net
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 167.04 210.528 256.104 283.501 302.133
Cash and Short Term Investments 155.485 202.103 248.386 275.638 301.52
Cash 36.632 26.371 29.117 8.377 24.779
Short Term Investments 118.853 175.732 219.269 267.261 276.741
Prepaid Expenses 11.555 8.425 7.718 7.863 0.613
Total Assets 168.529 210.662 256.502 284.256 302.312
Other Long Term Assets, Total 0.071 0.109 0.077 0.157 0.179
Total Current Liabilities 21.947 8.778 12.129 6.777 4.55
Accounts Payable 8.529 1.444 3.988 2.431 0.959
Accrued Expenses 13.418 7.334 8.141 4.346 3.591
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0
Other Current Liabilities, Total 0
Total Liabilities 23.207 8.778 12.158 7.137 4.562
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 1.26 0 0.029 0.36 0.012
Total Equity 145.322 201.884 244.344 277.119 297.75
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 445.267 425.614 412.589 405.803 401.09
Retained Earnings (Accumulated Deficit) -292.049 -223.182 -168.192 -128.697 -102.918
Other Equity, Total -1.102 -0.549 -0.054 0.012 -0.423
Total Liabilities & Shareholders’ Equity 168.529 210.662 256.502 284.256 302.312
Total Common Shares Outstanding 78.2573 78.2484 73.2159 72.4136 71.742
Property/Plant/Equipment, Total - Net 1.418 0.025 0.321 0.598
Preferred Stock - Non Redeemable, Net 0
Treasury Stock - Common -6.795
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 381.3 399.371 149.468 167.04 165.146
Cash and Short Term Investments 376.241 392.92 135.664 155.485 155.023
Cash 37.185 69.519 18.362 36.632 29.408
Short Term Investments 339.056 323.401 117.302 118.853 125.615
Prepaid Expenses 5.059 6.451 13.804 11.555 10.123
Total Assets 382.663 400.693 150.895 168.529 166.683
Property/Plant/Equipment, Total - Net 1.2 1.273 1.346 1.418 1.489
Other Long Term Assets, Total 0.163 0.049 0.081 0.071 0.048
Total Current Liabilities 13.405 13.478 15.649 21.947 14.061
Accounts Payable 5.711 5.611 3.799 8.529 3.142
Accrued Expenses 7.694 7.867 11.85 13.418 10.919
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 14.423 14.578 16.83 23.207 15.398
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.018 1.1 1.181 1.26 1.337
Total Equity 368.24 386.115 134.065 145.322 151.285
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 729.278 724.754 453.057 445.267 432.33
Retained Earnings (Accumulated Deficit) -353.339 -330.805 -311.58 -292.049 -272.49
Other Equity, Total -0.905 -1.04 -0.618 -1.102 -1.761
Total Liabilities & Shareholders’ Equity 382.663 400.693 150.895 168.529 166.683
Total Common Shares Outstanding 100.029 100.029 79.3191 78.2573 76.6885
Preferred Stock - Non Redeemable, Net 0 0 0 0
Treasury Stock - Common -6.795 -6.795 -6.795 -6.795 -6.795
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -68.867 -54.99 -39.495 -25.779 -22.063
Cash From Operating Activities -48.397 -47.586 -21.777 -24.752 -18.755
Non-Cash Items 10.281 10.331 10.001 4.81 2.485
Cash Interest Paid 0 0.081
Changes in Working Capital 10.189 -2.927 7.717 -3.783 0.823
Cash From Investing Activities 54.753 37.96 41.567 7.463 -265.729
Other Investing Cash Flow Items, Total 54.753 37.96 41.567 7.463 -265.729
Cash From Financing Activities 4.163 6.88 0.95 0.887 300.275
Financing Cash Flow Items 10.11 -0.753 -0.322 -0.224 -0.892
Issuance (Retirement) of Stock, Net -5.947 7.633 1.272 1.111 305
Issuance (Retirement) of Debt, Net 0 -3.833
Net Change in Cash 10.261 -2.746 20.74 -16.402 15.791
Foreign Exchange Effects -0.258
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -19.531 -68.867 -49.308 -33.535 -16.103
Cash From Operating Activities -24.643 -48.397 -37.471 -23.972 -10.53
Non-Cash Items 3.292 10.281 8.128 5.851 3.12
Changes in Working Capital -8.404 10.189 3.709 3.712 2.453
Cash From Investing Activities 2.198 54.753 47.493 20.599 1.619
Other Investing Cash Flow Items, Total 2.198 54.753 47.493 20.599 1.619
Cash From Financing Activities 4.184 4.163 -6.586 -6.596 -5.006
Financing Cash Flow Items 0.218 10.11 -0.489 -0.499 -0.499
Issuance (Retirement) of Stock, Net 3.966 -5.947 -6.097 -6.097 -4.507
Net Change in Cash -18.27 10.261 3.037 -10.145 -13.917
Foreign Exchange Effects -0.009 -0.258 -0.399 -0.176
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 14.9084 14912688 4053059 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.6545 5656088 4257899 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.091 5092488 1048298 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.818 4819376 -461568 2023-06-30 LOW
Ligand Pharmaceuticals Inc Corporation 3.615 3616077 -2449003 2023-03-29 LOW
Viking Global Investors LP Investment Advisor/Hedge Fund 3.5435 3544506 1589443 2023-06-30 MED
AllianceBernstein L.P. Investment Advisor/Hedge Fund 2.9607 2961561 2947905 2023-06-30 LOW
Boxer Capital, L.L.C. Hedge Fund 1.9994 2000000 0 2023-06-30 LOW
Lian (Brian) Individual Investor 1.9436 1944168 -45000 2023-05-01 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8459 1846439 983207 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.8226 1823120 -2014876 2023-06-30 HIGH
Wasatch Global Investors Inc Investment Advisor/Hedge Fund 1.709 1709475 4031 2023-06-30 LOW
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.3797 1380072 1355183 2023-06-30 LOW
Deerfield Management Company, L.P. Hedge Fund 1.1247 1125000 0 2023-06-30 MED
RTW Investments L.P. Investment Advisor/Hedge Fund 0.9997 1000000 0 2023-06-30 LOW
Victory Capital Management Inc. Investment Advisor/Hedge Fund 0.8189 819112 553792 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7858 786027 617307 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.7727 772910 240679 2023-06-30 LOW
Fidelity Investments Canada ULC Investment Advisor 0.7561 756326 14699 2023-06-30 MED
Eventide Asset Management, LLC Investment Advisor 0.7498 750000 750000 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Viking Therapeutics, Inc. Company profile

About Viking Therapeutics Inc

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Viking Therapeutics Inc revenues was not reported. Net loss increased 39% to $55M. Higher net loss reflects Other Research and Development. increase of 42% to $43.4M (expense), Interest Income - Net decrease of 78% to $703K (income), Stock-based Compensation in R&D increase of 19% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.54 to -$0.71.

Industry: Bio Therapeutic Drugs

9920 Pacific Heights Blvd, Suite 350
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

XRP/USD

0.65 Price
+8.740% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

62,120.75 Price
-0.950% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,286.90 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Oil - Crude

79.49 Price
+1.850% 1D Chg, %
Long position overnight fee 0.0266%
Short position overnight fee -0.0485%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading